Thanks @RebeccaKSWong, looking forward to great treatments in Canada and worldwide…let’s do it 💪

80 years ago, the world witnessed the devastating impact of two atomic bombs on Japan 💔 Atoms, once used to destroy, can also be used to heal 💊✨ In #Theranostics, #OurFriendTheAtom helps us treat cancer 🎯, restoring hope 🌱, and giving patients more time with loved ones ♥️.

An ongoing first-in-human trial aims to establish the safety, dosimetry, and preliminary efficacy of ¹⁷⁷Lu-HTK03170 in patients with PSMA-positive #mCRPC. Read more: https://t.co/sPH3Ebx2Pu #NuclearMedicine #RPTherapy #ProstateCancer @BCCancer @sara_harsini

Computational nuclear oncology toward precision #RPTherapy: Current tools, techniques, & uncharted territories. https://t.co/bCzZihOFRE @ArmanRahmim @babaksaboury @JoyitaDutta @DrGeoffCurrie @JhaLabWashU @CarlosUribeM @JuliaBroschLenz @EmilieRoncali

First patient treated with #Pluvicto™ in pre-chemotherapy setting following @FDA approval. Dr. Steven Finkelstein joins @zklaassen_md to discuss the recent approval and his team's achievement of treating the first U.S. patient under this new indication. #WatchNow on UroToday >

BIG NEWS! Yesterday the FDA expanded the indication for lutetium-177 vipivotide tetraxetan (Pluvicto), allowing its use before taxane-based chemotherapy. The new approval triples Pluvicto’s eligible patient population. More here: https://t.co/rFs5M8lO6v

A summary of my last 24h stranded in #LAX thanks to @WestJet. Delayed 5 times until flight was cancelled. Rebooked to today and delayed again 3 more times. Zero compensation…not even a bottle of water.

Recent Data of #Theranostics published in the @TheLancet: LuPSMA therapy can improve PFS of patients with metastatic prostate cancer before trying chemotherapy or also as a booster to chemotherapy. Kudos to the trialists! https://t.co/RScbQkRPeY https://t.co/GsWSXBo3Zg

SPECT deserves RESPECT! @drlouiseemmett makes the argument that it is a powerful tool for theranostics ➤ enabling early, personalised treatment response evaluation ➤ optimizes outcomes by guiding therapy adjustments. ✓practical advantages over serial PET.

9/ None of this would be possible without our incredible team at #Qurit and our collaborators. A huge thanks to @lukepolson97 for leading and making this dream a reality and to everyone who contributed along the way! 💙 Let us know your thoughts or questions below! #theranostics

8/ 🛠️ This project is more than software, it's a tool to accelerate innovation in medical imaging. Explore it on https://t.co/Ft7dcXU2q8 and check the documentation at https://t.co/nxlxJ0TQq5 We’d love your feedback and/or collaboration ideas. 🚀

7/ 💡 What’s next for #PyTomography? While we continue expanding clinical #PET and #SPECT capabilities, we’re excited to invite YOU to try the #3DSlicer extension, already available for download. Join the community and explore its full potential! https://t.co/V4XUeMHlsY

6/ Example 2: #PET image reconstruction 🔬 We integrated LM-TOF reconstruction and the DIPRecon algorithm, leveraging neural networks for improved resolution and noise reduction.

5/ Example 1: Clinical #SPECT Imaging 🧠 We validated #PyTomography achieving great quantitative results in a vendor-neutral and precise manner; a great tool for researchers!

4/ 🌟 Key Features: - Modular design for #SPECT, #PET, and #CT reconstruction - #PyTorch integration for deep learning - #GPU-accelerated fast computations - A #3DSlicer extension for intuitive, GUI-based workflows

3/ Why does this matter? 🤔 Medical image reconstruction is critical for diagnosis and therapy (#theranostics). #PyTomography supports modern and AI-based algorithms while being accessible and reproducible, a true #OpenSource 🌐 tool!

2/ 🚀 #PyTomography is an open-source Python library for GPU-accelerated medical image reconstruction. It empowers researchers to explore cutting-edge methods in emission tomography with ease. 📜 https://t.co/t1IvNo2dpJ

1/ As a PhD student, I dreamed of #reconstruction software that would let us test #SPECT and #PET quantification methods in a simple, open, and vendor-neutral way. That dream inspired #PyTomography, and today, thanks to @lukepolson97 et. al. PhD's work, it’s a reality. 🧵👇

Moving toward precision response assessment and dynamic risk startification by SPECT/CT in mCRPC receiving LuPSMA! #PSMA #Theranostics @fredhutch @UW @drlouiseemmett @DrMHofman @thomashopemd https://t.co/UIe74wOz17

After PSMAfore and SPLASH, The ECLIPSE trial also met its primary endpoint Hopefully we will get LuPSMA therapy approved for chemotherapy-naive mCRPC patients one day. #PSMA #theranostics #prostatecancer @Curium_Pharma https://t.co/R1bPnn4TL7

SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617